Over the past 12 months, shares of Amarin (AMRN 2.68%) have dropped 45% amid uncertainty around Vascepa's NCE status, buyout speculation that never came to fruition, and question marks around the efficacy of fish oil. The company is hoping to get expanded approval for Vascepa and announced today that the FDA's advisory committee meeting date has been set. In the following video, health-care analyst Max Macaluso discusses the importance of this meeting and the risks and opportunities up ahead for this speculative biotech.
Will Amarin's Fish Oil Drug Slip Past the FDA a Second Time?
By Max Macaluso – Jun 19, 2013 at 7:00PM
NASDAQ: AMRN
Amarin Plc
Market Cap
$326M
Today's Change
(-2.68%) $0.42
Current Price
$15.25
Price as of November 7, 2025 at 12:59 PM ET
The advisory committee meeting date for the ANCHOR indication is now set.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo